CLINICAL_TRIALS
trial_result
· 2015-03-06
Clinical Trial Update: S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia [Phase 2]
Summary
Phase 2 trial S0117 evaluating gemtuzumab ozogamicin plus cytarabine for relapsed acute myeloid leukemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: SWOG Cancer Research Network | Conditions: Leukemia | Phase 2 | Status: COMPLETED